Small-cell lung cancer
https://doi.org/10.21886/2219-8075-2017-8-4-6-13
Abstract
Lung cancer – one of the most common malignancies in the world. Currently, domestic publications addressing issues of classifi cation, clinic, diagnosis, treatment, a form of lung cancer - non-small cell cancer, is extremely small. Th erefore, our work makes up to some extent this gap. Th is review of literature devoted to small-cell lung cancer, the tumor has an aggressive clinical course and poor prognosis. Th e review considers the epidemiology, clinical and morphological classifi cation of small cell lung cancer; it is recommended the most appropriate clinical classifi cation, which classifi es tumors into two forms — limited or local and extensive. Th e paper focuses on the standard options of treatment of limited form and extensive form of non-small cell lung cancer. In the treatment of limited form confi rmed the primary role of chemotherapy with radiation therapy, combination chemotherapy, surgery followed by chemotherapy or chemoradiotherapy. For the treatment of extensive form shown in the use of such treatment options as combination chemotherapy and radiotherapy. It noted the successes and shortcomings in the treatment of this tumor chemotherapy, radiation therapy, and combination therapy, and also points to the development of new schemes and treatment combinations with greater effi ciency and less toxicity for patients. Separately, the issues of treatment of small cell lung cancer recurrence and noted the major role in the treatment of chemotherapy and palliative care. Th e importance of brain irradiation in reducing recurrence and increase survival in this pathology.
About the Authors
Nicolay G. Bakhmutsky
Kuban State Medical University
Russian Federation
Krasnodar, Russia
Competing Interests:
Russian Federation
Krasnodar, Russia
Competing Interests:
Авторы заявляют об отсутствии конфликта интересов.
Vladimir A. Porkhanov
Kuban State Medical University
Russian Federation
Krasnodar, Russia
Russian Federation
Krasnodar, Russia
Vadim N. Bodnya
Kuban State Medical University
Russian Federation
Krasnodar, Russia
Russian Federation
Krasnodar, Russia
Rostislav P. Schiryayev
Kuban State Medical University
Russian Federation
Krasnodar, Russia
Russian Federation
Krasnodar, Russia
References
1. Zlokachestvennye novoobrazovanija v Rossii v 2014 godu (Zabolevaemost’ i smertnost’). Moscow, 2016. (In Russ.)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107
3. Kelley MJ, Bogart JA, Hodgson LD, Ansari RH, Atkins JN, Pang H, et al. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J.Th orac.Oncol. 2013;8(1):102-8. doi: 10.1097/JTO.0b013e31827628e1
4. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J. Clin. Oncol. 2004;22(16):3248-54. DOI: 10.1200/JCO.2004.11.089
5. Salama JK, Hodgson L, Pang H, Urbanic JJ, Blackstock AW, Schild SE, et al. A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy CALGB 30904. J.Th orac.Oncol. 2013;8(8):1043-9. doi: 10.1097/JTO.0b013e318293d8a4
6. Lung. In: Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
7. Aynaci O, Canyilmaz E, Serdar L, Kandaz M, Bahat ZM, Yoney A. Survival and prognostic factors in limited stage small cell lung cancer: A retrospective study from northeast Turkey. Cancer Res. 2016;12(1):238-243. doi: 10.4103/0973-1482.151446
8. Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, et al. Treatment of small cell lang cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat. Rev. 2004;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006
9. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J. Clin. Oncol. 2003;21(8):1544-9. doi: 10.1200/JCO.2003.10.089
10. Chandra V, Allen MS, Nichols FC, Deschamps C, Cassivi SD, Pairolero PC. Th e role of pulmonary resection in small cell lung cancer. Mayo Clin. Proc. 2006;81(5):619-24. doi: 10.4065/81.5.619
11. Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J. Clin. Oncol. 2002;20(14):3054-60. DOI: 10.1200/JCO.2002.12.071
12. Bychkov MB, Dgebuadze EN, Bol’shakova SA. Melkokletochnyi rak legkogoю Prakticheskaya onkologiya. 2005;6(4):213-219. (In Russ.)
13. Slotman BJ, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N. Engl. J. Med. 2007;357(7):664-72. DOI: 10.1056/NEJMoa071780
14. Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385(9962):36-42. doi: 10.1016/S0140-6736(14)61085-0
15. Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst. Rev. (4):CD006849, 2008. doi: 10.1002/14651858.CD006849.pub3
16. Bagrova SG, Bychkov MB, Gorbunova VA, Kuzminov AE, Naskhletashvili DR. Comparative evaluation of diff erent regimen of platinum-based chemotherapy in treatment of advanced small cell lung cancer (experience of chemotherapy department N.N.Blokhin Russian Cancer Research Center RAMS). Russian Journal of Oncology. 2013;(2):4-10. (In Russ.)
17. Spiro SG, James LE, Rudd RM, Trask CW, Tobias JS, Snee M, et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J.Clin.Oncol. 2006;24(24):3823-30. DOI: 10.1200/JCO.2005.05.3181
18. De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P. Systematic review and metaanalysis of randomized, controlled trials of the timing of chest radiotherapy in patients with limited stage, smalllung cancer. Ann. Oncol. 2006;17(4):543-52. DOI: 10.1093/annonc/mdj094
19. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J.Clin.Oncol. 2004;22(23):4837-45. DOI: 10.1200/JCO.2004.01.178
20. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist. 2004;9(6):665-72. DOI: 10.1634/theoncologist.9-6-665
21. Pijls-Johannesma M, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst. Rev. 2005;(1):CD004700. DOI: 10.1002/14651858.CD004700.pub2
22. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, Lutgens L, et al. Time between the fi rst day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J.Clin.Oncol. 2006;24(7):1057-63. DOI: 10.1200/JCO.2005.02.9793
23. Gulidov IA, Zolotkov AG, Mardynsky YS, Ivanova IN, Kursova LV, et al. Comparison of conventional radiatiotherapy and accelerated hyperfractionated radiatiotherapy in chemoradiation treatment for small cell lung cancer. Siberian journal of oncology. 2013;(1):12-15. (In Russ.)
24. Bogart JA, Herndon JT, Lyss AP, Watson D, Miller AA, Lee ME, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-disease small-cell lung cancer; analysis of Cancer and Leukemia Group B study 39808. Int.J.Radiat.Oncol.Biol.Phys. 2004;59(2):460-8. DOI: 10.1016/j.ijrobp.2003.10.021
25. Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, et al. Phase II trial of paclitaxel-topotecanetoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. J.Th orac.Oncol. 2007;2(7):645-51. DOI: 10.1097/JTO.0b013e318074bbf5
26. Kolbanov KI, Trakhtenberg AKh, Pikin OV. Vozmozhnosti khirurgii pri rezektabel’nom melkokletochnom rake legkogo. Onkologiya. Zhurnal im. P.A. Gertsena. 2017;6(3):67-75. (in Russ.)
27. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, et al. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease smallcell lung cancer: JCOG 9702. Br. J. Cancer. 2007;97(2):162-9. DOI: 10.1038/sj.bjc.6603810
28. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie TJr, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J. Clin. Oncol. 2006;24(13):2038-43. DOI: 10.1200/JCO.2005.04.8595
29. Lara PN, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol. 2009;27(15):2530-5. doi: 10.1200/JCO.2008.20.1061
30. Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, et al. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as fi rst-line therapy for extensivedisease small-cell lung cancer. Ann. Oncol. 2011;22(8):1798-804. doi: 10.1093/annonc/mdq652
31. Zatloucal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann. Oncol. 2010;21(9):1810-6. doi: 10.1093/annonc/mdq036
32. Jiang J, Liang X, Zhou X, Huang L, Huang R, et al. A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J. Th orac. Oncol. 2010;5(6):867-73.
33. Guo S, Liang Y, Zhou Q. Complement and correction for meta-analysis of patients with extensive-stage small cell lung cancer managed with irinotecan/cisplatin versus etoposide/cisplatin as fi rst-line chemotherapy. J. Th orac. Oncol. 2011;6(2):406-8. doi: 10.1097/JTO.0b013e3182061d8c
34. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J. Clin. Oncol. 2007;25(15):2086-92. DOI: 10.1200/JCO.2006.08.3998
35. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J. Clin. Oncol. 2005;23(16):3752-9. DOI: 10.1200/JCO.2005.09.071
36. Th atcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colonystimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J. Clin. Oncol. 2000;18(2):395-404. DOI: 10.1200/JCO.2000.18.2.395
37. Lorigan P, Woll PJ, O’Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J. Natl. Cancer Inst. 2005;97(9):666-74. DOI: 10.1093/jnci/dji114
38. Buchholz E, Manegold C, Pilz L, Th atcher N, Drings P. Standard versus dose-intensifi ed chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J. Th orac. Oncol. 2007;2(1):51-8. DOI: 10.1097/JTO.0b013e31802baf9d
39. Shivnani AT. Prophylactic cranial irradiation in smallcell lung cancer. N. Engl. J. Med. 2007;357(19):30-34. DOI: 10.1056/NEJMc072691
40. Davies AM, Ewans WK, Mackay JA, Shepherd FA. Treatment of recurrent small cell lung cancer. Hematol. Oncol. Clin. Noth. Am. 2004;18(2):387-416. DOI: 10.1016/j.hoc.2003.12.010
41. van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlösser NJ, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann. Oncol. 2001;12(4):557-61.
42. Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, et al. Open-label, multicenter, randomized phase III study comparing oral topotecan/cisplatin versus etoposide/ cisplatin as treatment for chemotherapy-native patients with extensive-disease small-cell lung cancer. J. Clin. Oncol. 2006;24(13):2044-51. DOI: 10.1200/JCO.2005.03.3332
43. Rocha-Lima CM, Herndon JE, Lee ME, Atkins JN, Mauer A, et al. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Ann. Oncol. 2007;18(2):331-7. DOI: 10.1093/annonc/mdl375
Review
For citations:
Bakhmutsky N.G., Porkhanov V.A., Bodnya V.N., Schiryayev R.P. Small-cell lung cancer. Medical Herald of the South of Russia. 2017;8(4):6-13. (In Russ.) https://doi.org/10.21886/2219-8075-2017-8-4-6-13
Views:
884
Email this article 